AbbVie beats Q3 earnings and sales estimates and raises 2026 EPS view; stock rises
FROM THE WIRE · FINANCE.YAHOO.COM
AbbVie Inc. ABBV reported adjusted earnings per share (EPS) of $3.82 for the third quarter of 2026, beating the Zacks Consensus Estimate of $3.74. The reported metric even surpassed management's guidance of $3.73-$3.77. Earnings surged 105.4% year over year, with the prior-year…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA large pharma raising its full-year guidance can move the healthcare sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Adjusted third quarter 2026 EPS was $3.82 versus a Zacks consensus of $3.74.
- 02Revenue of $17.4 billion topped the consensus of $17.37 billion.
- 03Skyrizi sales rose 22.9% to $5.78 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets